Karyopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
Karyopharm Therapeutics (KPTI) Tops Q1 EPS by 10c
May 5, 2022 7:24 AM EDTKaryopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($0.53), $0.10 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $47.7 million versus the consensus estimate of $34.17 million.
For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.
... More